TNDM Stock Forecast & Price Target

Tandem Diabetes Care has demonstrated impressive financial performance, achieving a top-line revenue of $252.4 million, reflecting a year-over-year growth of 20.6%, which surpasses consensus expectations. The company is positioned for continued growth with a revenue forecast of $725–730 million, supported by increased warranty renewals, stable supply sales, and growth in new pump starts. The recent FDA clearance for Type 2 diabetes has significantly expanded Tandem's addressable market, reinforcing its potential for sustained double-digit revenue growth amid a backdrop of high customer satisfaction and retention in the U.S. market.

Tandem Diabetes Care has reported ongoing significant operating losses since its inception, raising concerns about its ability to achieve sustained profitability. The company recently provided initial 2025 guidance that appears underwhelming, citing seasonal trends and expected sales force disruptions, which could hinder its expansion in both the U.S. and international markets. Additionally, factors such as competitive pressures, potential reimbursement challenges, and uncertainties in global economic conditions may further complicate the company's financial outlook, contributing to the stock's notable decline in after-hours trading.